Palonosetron News and Research

RSS

Palonosetron is a second-generation 5-hydroxytryptamine 3 (5-HT3)-receptor antagonist that has shown better efficacy than ondansetron and dolasetron in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy, and similar efficacy to ondansetron in preventing CINV in patients receiving highly emetogenic chemotherapy.

Palonosetron effective anti-emetic for paediatric chemotherapy patients

Palonosetron 20 μg/kg is noninferior to ondansetron for the control of chemotherapy-induced vomiting and nausea during the acute phase of the first treatment cycle in paediatric patients with cancer, research shows.

26 Jan 2016

Helsinn's Akynzeo for CINV prevention receives EC approval

Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.

2 Jun 2015

Helsinn launches Helsinn Integrative Care division at ASCO Annual Meeting

Helsinn, the Swiss Group focused on building quality cancer care, announces today that its recently launched Helsinn Integrative Care division is meeting the cancer community at booth 6033 at the American Society of Clinical Oncology Annual Meeting, May 29-June 2, Chicago, Illinois.

2 Jun 2015

Helsinn Group announces European approval of ALOXI (palonosetron HCl) injection for paediatric use

Helsinn Group, the Swiss Group focused on building quality cancer care, today announces that the European Commission has endorsed the Committee for Medicinal Products for Human Use's Opinion recommending the approval of ALOXI (palonosetron HCl) injection for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, in paediatric patients one month of age and older.

27 May 2015

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Australian biopharmaceutical company Specialised Therapeutics Australia and Helsinn, a Swiss group focused on building quality cancer care, announce that the Therapeutic Goods Administration has approved AKYNZEO for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy.

8 May 2015

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Helsinn Group and Eisai Inc. announced today that the Food and Drug Administration (FDA) approved AKYNZEO® for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.

13 Oct 2014

ALOXI injection receives FDA approval for prevention of nausea, vomiting associated with cancer chemotherapy

Eisai Inc. and Helsinn Group today announced the Food and Drug Administration (FDA) approval of ALOXI (palonosetron HCl) injection for the prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy, in children aged 1 month to less than 17 years.

29 May 2014

Helsinn, Mundipharma sign distribution and license agreement for investigational therapy

Helsinn and Mundipharma announce the signature of a new, exclusive license and distribution agreement, covering China, Hong Kong and Macao, for netupitant-palonosetron fixed dose combination, a Helsinn product under development for the treatment of chemotherapy-induced nausea and vomiting.

19 Dec 2013

STA announces results from ABRAXANE plus gemcitabine phase III trial on pancreatic cancer

Australian biopharmaceutical company Specialised Therapeutics Australia announces that a phase III clinical trial of world leading breast cancer drug ABRAXANE (nanoparticle albumin-bound paclitaxel) in combination with current standard of care gemcitabine in patients with advanced pancreatic cancer has demonstrated substantially improved survival times, with double the number of patients surviving two years.

23 Jan 2013

Risk model predicts illness after ambulatory surgery

A marked proportion of patients undergoing ambulatory surgery suffer postdischarge nausea and vomiting, say US scientists who have developed a simplified risk score to identify patients who may benefit from long-acting prophylactic therapy.

9 Aug 2012

A.P. Pharma announces additional data from APF530 Phase 3 study on CINV

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced additional data from the Company's Phase 3 study of APF530 for the prevention of chemotherapy-induced nausea and vomiting (CINV).

29 Jun 2012

Results from A.P. Pharma’s APF530 Phase 3 trial on CINV

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that an abstract analyzing a subset of efficacy results from its Phase 3 trial of APF530 has been published in conjunction with the American Society of Clinical Oncology's (ASCO) 2012 Annual Meeting.

1 Jun 2012

Helsinn commences Netupitant/Palonosetron Phase III combination study in CINV

Helsinn Group and Eisai Inc. announced today that Helsinn has commenced a multi-centered Phase III clinical study program investigating the Netupitant/Palonosetron (300mg/0.50mg) oral fixed-dose combination for the prevention of chemotherapy-induced nausea and vomiting.

23 Sep 2011

New palonosetron-aprepitant trial data on chemotherapy induced nausea, vomiting presented at EHA

New data presented at the European Hematology Association (EHA) 2011 Annual Meeting in London show better control of nausea and vomiting with the combination palonosetron plus aprepitant when compared to granisetron in patients receiving multiday highly emetogenic conditioning chemotherapy regimens - Significantly higher the complete response during the acute, delayed and overall periods.

8 Jun 2011

Simcere subsidiary receives Chinese SFDA approval to manufacture and market Palonosetron

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that its subsidiary company Simcere Dongyuan Pharmaceutical Co., Ltd. has recently received SFDA new drug certification and registration approval to manufacture and market Palonosetron material and injections in China.

12 Aug 2010

New Zealand MEDSAFE approves ABRAXANE for metastatic breast cancer

Abraxis BioScience, Inc., a fully integrated, global biotechnology company, and Specialised Therapeutics Ltd. today announced that MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority, has approved for marketing ABRAXANE® (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer after failure of anthracycline therapy.

29 Jul 2010

Helsinn Healthcare S.A., Eisai announce signing of licensing agreement

Helsinn Healthcare S.A. and Eisai Inc. today announce the signing of a licensing agreement granting Eisai Inc. commercialization rights for a new product for potential use in the prevention of chemotherapy-induced nausea and vomiting in the United States.

9 Jun 2010

TESARO secures $60 million in start-up funding to acquire, develop and commercialize cancer therapeutics

TESARO, Inc., an oncology-focused biopharmaceutical company, today announced that it has secured $60 million in start-up funding to acquire, develop and commercialize cancer therapeutics and supportive care products. Participants in a $20 million Series A financing included New Enterprise Associates (NEA) and TESARO management; additionally, NEA has reserved $40 million to support company growth.

27 May 2010

A.P. Pharma's NDA for APF530 in prevention of CINV: FDA issues Complete Response Letter

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for APF530 in the prevention of both acute and delayed onset chemotherapy-induced nausea and vomiting.

19 Mar 2010

A.P. Pharma announces financial results for its third quarter ended September 30, 2009

A.P. Pharma, Inc., a specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2009.

16 Nov 2009